Logo image of KNSA

KINIKSA PHARMACEUTICALS INTE (KNSA) Stock Fundamental Analysis

NASDAQ:KNSA - GB00BRXB0C07 - Common Stock

33.49 USD
-0.01 (-0.03%)
Last: 8/29/2025, 8:00:02 PM
33.87 USD
+0.38 (+1.13%)
After Hours: 8/29/2025, 8:00:02 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to KNSA. KNSA was compared to 547 industry peers in the Biotechnology industry. KNSA has an excellent financial health rating, but there are some minor concerns on its profitability. KNSA is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes KNSA very considerable for growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

KNSA had positive earnings in the past year.
In the past year KNSA had a positive cash flow from operations.
In multiple years KNSA reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: KNSA reported negative operating cash flow in multiple years.
KNSA Yearly Net Income VS EBIT VS OCF VS FCFKNSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

KNSA has a Return On Assets of 0.72%. This is amongst the best in the industry. KNSA outperforms 89.76% of its industry peers.
The Return On Equity of KNSA (0.97%) is better than 90.86% of its industry peers.
The Return On Invested Capital of KNSA (0.65%) is better than 90.68% of its industry peers.
Industry RankSector Rank
ROA 0.72%
ROE 0.97%
ROIC 0.65%
ROA(3y)11.71%
ROA(5y)-15.78%
ROE(3y)13.22%
ROE(5y)-19.49%
ROIC(3y)N/A
ROIC(5y)N/A
KNSA Yearly ROA, ROE, ROICKNSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

Looking at the Profit Margin, with a value of 0.90%, KNSA belongs to the top of the industry, outperforming 90.31% of the companies in the same industry.
KNSA's Operating Margin of 0.85% is amongst the best of the industry. KNSA outperforms 90.31% of its industry peers.
Looking at the Gross Margin, with a value of 85.93%, KNSA belongs to the top of the industry, outperforming 88.85% of the companies in the same industry.
KNSA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 0.85%
PM (TTM) 0.9%
GM 85.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
KNSA Yearly Profit, Operating, Gross MarginsKNSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so KNSA is destroying value.
KNSA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for KNSA has been increased compared to 5 years ago.
There is no outstanding debt for KNSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KNSA Yearly Shares OutstandingKNSA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
KNSA Yearly Total Debt VS Total AssetsKNSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 9.29 indicates that KNSA is not in any danger for bankruptcy at the moment.
KNSA's Altman-Z score of 9.29 is amongst the best of the industry. KNSA outperforms 84.64% of its industry peers.
There is no outstanding debt for KNSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 9.29
ROIC/WACC0.07
WACC9.23%
KNSA Yearly LT Debt VS Equity VS FCFKNSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

KNSA has a Current Ratio of 3.57. This indicates that KNSA is financially healthy and has no problem in meeting its short term obligations.
KNSA's Current ratio of 3.57 is in line compared to the rest of the industry. KNSA outperforms 41.68% of its industry peers.
A Quick Ratio of 3.16 indicates that KNSA has no problem at all paying its short term obligations.
KNSA has a Quick ratio of 3.16. This is comparable to the rest of the industry: KNSA outperforms 40.59% of its industry peers.
Industry RankSector Rank
Current Ratio 3.57
Quick Ratio 3.16
KNSA Yearly Current Assets VS Current LiabilitesKNSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 125.00% over the past year.
KNSA shows a strong growth in Revenue. In the last year, the Revenue has grown by 56.18%.
Measured over the past years, KNSA shows a very strong growth in Revenue. The Revenue has been growing by 122.27% on average per year.
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%483.33%
Revenue 1Y (TTM)56.18%
Revenue growth 3Y122.27%
Revenue growth 5YN/A
Sales Q2Q%51.65%

3.2 Future

KNSA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.33% yearly.
KNSA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.93% yearly.
EPS Next Y170.9%
EPS Next 2Y116.9%
EPS Next 3Y77.75%
EPS Next 5Y47.33%
Revenue Next Year34.22%
Revenue Next 2Y35.21%
Revenue Next 3Y28%
Revenue Next 5Y21.93%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
KNSA Yearly Revenue VS EstimatesKNSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
KNSA Yearly EPS VS EstimatesKNSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 837.25, the valuation of KNSA can be described as expensive.
KNSA's Price/Earnings ratio is rather cheap when compared to the industry. KNSA is cheaper than 89.76% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.08. KNSA is valued rather expensively when compared to this.
KNSA is valuated rather expensively with a Price/Forward Earnings ratio of 20.30.
KNSA's Price/Forward Earnings ratio is rather cheap when compared to the industry. KNSA is cheaper than 93.24% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.72. KNSA is around the same levels.
Industry RankSector Rank
PE 837.25
Fwd PE 20.3
KNSA Price Earnings VS Forward Price EarningsKNSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 200 400 600 800

4.2 Price Multiples

89.03% of the companies in the same industry are more expensive than KNSA, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, KNSA is valued cheaply inside the industry as 93.60% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 37.33
EV/EBITDA 344.51
KNSA Per share dataKNSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of KNSA may justify a higher PE ratio.
A more expensive valuation may be justified as KNSA's earnings are expected to grow with 77.75% in the coming years.
PEG (NY)4.9
PEG (5Y)N/A
EPS Next 2Y116.9%
EPS Next 3Y77.75%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KNSA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KINIKSA PHARMACEUTICALS INTE

NASDAQ:KNSA (8/29/2025, 8:00:02 PM)

After market: 33.87 +0.38 (+1.13%)

33.49

-0.01 (-0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-29 2025-07-29/bmo
Earnings (Next)10-21 2025-10-21
Inst Owners94.65%
Inst Owner Change-7.48%
Ins Owners3.76%
Ins Owner Change-0.43%
Market Cap2.48B
Analysts86.67
Price Target45.7 (36.46%)
Short Float %5.97%
Short Ratio2.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)141.63%
Min EPS beat(2)23.78%
Max EPS beat(2)259.48%
EPS beat(4)2
Avg EPS beat(4)-1537.64%
Min EPS beat(4)-5782.35%
Max EPS beat(4)259.48%
EPS beat(8)4
Avg EPS beat(8)-731.38%
EPS beat(12)8
Avg EPS beat(12)-432.45%
EPS beat(16)11
Avg EPS beat(16)-320.68%
Revenue beat(2)2
Avg Revenue beat(2)4.5%
Min Revenue beat(2)4.01%
Max Revenue beat(2)4.99%
Revenue beat(4)2
Avg Revenue beat(4)1.26%
Min Revenue beat(4)-2.63%
Max Revenue beat(4)4.99%
Revenue beat(8)5
Avg Revenue beat(8)3.77%
Revenue beat(12)9
Avg Revenue beat(12)8.7%
Revenue beat(16)11
Avg Revenue beat(16)8.8%
PT rev (1m)16.06%
PT rev (3m)22.5%
EPS NQ rev (1m)51.71%
EPS NQ rev (3m)71.14%
EPS NY rev (1m)-41.52%
EPS NY rev (3m)-39.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 837.25
Fwd PE 20.3
P/S 4.69
P/FCF 37.33
P/OCF 37.07
P/B 5.01
P/tB 5.18
EV/EBITDA 344.51
EPS(TTM)0.04
EY0.12%
EPS(NY)1.65
Fwd EY4.93%
FCF(TTM)0.9
FCFY2.68%
OCF(TTM)0.9
OCFY2.7%
SpS7.14
BVpS6.68
TBVpS6.47
PEG (NY)4.9
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.72%
ROE 0.97%
ROCE 0.82%
ROIC 0.65%
ROICexc 1.5%
ROICexgc 1.61%
OM 0.85%
PM (TTM) 0.9%
GM 85.93%
FCFM 12.56%
ROA(3y)11.71%
ROA(5y)-15.78%
ROE(3y)13.22%
ROE(5y)-19.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
F-Score6
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 30.43%
Cap/Sales 0.09%
Interest Coverage 250
Cash Conversion 1120.09%
Profit Quality 1388.12%
Current Ratio 3.57
Quick Ratio 3.16
Altman-Z 9.29
F-Score6
WACC9.23%
ROIC/WACC0.07
Cap/Depr(3y)8.83%
Cap/Depr(5y)180.67%
Cap/Sales(3y)0.05%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%483.33%
EPS Next Y170.9%
EPS Next 2Y116.9%
EPS Next 3Y77.75%
EPS Next 5Y47.33%
Revenue 1Y (TTM)56.18%
Revenue growth 3Y122.27%
Revenue growth 5YN/A
Sales Q2Q%51.65%
Revenue Next Year34.22%
Revenue Next 2Y35.21%
Revenue Next 3Y28%
Revenue Next 5Y21.93%
EBIT growth 1Y116.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year202.02%
EBIT Next 3Y109.32%
EBIT Next 5YN/A
FCF growth 1Y56.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.64%
OCF growth 3YN/A
OCF growth 5YN/A